AI
IONS icon

Allostery Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Allostery Investments’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,000
Closed -$1.06M – 31
2025
Q1 		$1.06M Sell
35,000
-30,000
-46% -$982K 1.52% 17
2024
Q4 		$2.27M Buy
+65,000
New +$2.43M 2.37% 14

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Allostery Investments's IONS Position: Q2 2025 in Review

Allostery Investments sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 35,000 shares — an estimated $1.06M sold.

Allostery Investments first reported a position in IONS in Q4 2024 and held it in 2 quarters. The position peaked at $2.27M in Q4 2024. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

  • Allostery Investments reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Allostery Investments sold 35,000 Ionis Pharmaceuticals shares in Q2 2025, an estimated $1.06M.
  • Allostery Investments first reported a position in Ionis Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Allostery Investments's Ionis Pharmaceuticals position peaked at $2.27M in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.